First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases
Open Access
- 4 February 2017
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 73 (5) , 581-591
Abstract
Purpose PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans. Methods These phase I, randomised, double-blind, placebo-controlled, single-centre studies (NCT02303509, NCT02207595) evaluated single and multiple oral doses of seletalisib (5–90 mg QD and 30 mg BID) in healthy adults and subjects with mild-to-moderate psoriasis (Study-1). Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies. Results Seletalisib was well tolerated at doses ≤15 mg (Study-1) and ≤45 mg QD (Study-2) for 14 days. No safety concerns or dose-limiting toxicities were identified (Study-1). Incidence of gastrointestinal-related AEs was not dose related but higher incidences of rash AEs were associated with higher-dose seletalisib (Study-2 rash AEs: 18 in 12 seletalisib-treated subjects versus 1 in 1 placebo-treated subject). Mean seletalisib plasma concentration-time profiles increased with increasing doses after single and multiple dosing, with no major deviations from dose-proportionality. There was no unexpected accumulation or loss of exposure after multiple dosing (time-independent pharmacokinetic profile). Apparent t 1/2 values were supportive of once-daily dosing (geometric mean t1/2: Study-1, 17.7–21.1 h; Study-2, 18.1–22.4 h). No clinically significant food effect was observed (Study-1). Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue. Conclusions Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.Keywords
Funding Information
- UCB Pharma
This publication has 26 references indexed in Scilit:
- Rules of engagement: distinct functions for the four class I PI3K catalytic isoforms in immunityAnnals of the New York Academy of Sciences, 2013
- The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic DiseasesThe Open Rheumatology Journal, 2012
- Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasisCell Death & Disease, 2012
- Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignanciesFrontiers in Immunology, 2012
- PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humansBlood, 2010
- PsoriasisNew England Journal of Medicine, 2009
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic CellsJournal of Investigative Dermatology, 2009
- T-Helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and PsoriasisJournal of Investigative Dermatology, 2008
- Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3KTrends in Immunology, 2007
- Circulating basophils in normal subjects and in subjects with hay feverJournal of Allergy and Clinical Immunology, 1976